-
1
-
-
0031876331
-
Survival and disease complications in thalassemia major
-
Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappellini MD, Verlato G (1998) Survival and disease complications in thalassemia major. Ann N Y Acad Sci 850:227-231
-
(1998)
Ann. N. Y. Acad. Sci.
, vol.850
, pp. 227-231
-
-
Borgna-Pignatti, C.1
Rugolotto, S.2
De Stefano, P.3
Piga, A.4
Di Gregorio, F.5
Gamberini, M.R.6
Sabato, V.7
Melevendi, C.8
Cappellini, M.D.9
Verlato, G.10
-
2
-
-
0033536288
-
The β-thalassemias
-
Olivieri NF (1999) The β-thalassemias. N Engl J Med 341:99-109
-
(1999)
N. Engl. J. Med.
, vol.341
, pp. 99-109
-
-
Olivieri, N.F.1
-
3
-
-
0030048681
-
Results of long-term iron-chelating therapy
-
Gabutti V, Piga A (1996) Results of long-term iron-chelating therapy. Acta Haematol 95:26-36
-
(1996)
Acta Haematol.
, vol.95
, pp. 26-36
-
-
Gabutti, V.1
Piga, A.2
-
4
-
-
0028861997
-
Chelation therapy in β-thalassemia: The benefits and limitations of desferrioxamine
-
Giardina PJ, Grady RW (1995) Chelation therapy in β-thalassemia: the benefits and limitations of desferrioxamine. Semin Hematol 32:304-312
-
(1995)
Semin. Hematol.
, vol.32
, pp. 304-312
-
-
Giardina, P.J.1
Grady, R.W.2
-
6
-
-
0035725868
-
Practical management of iron overload
-
Porter JB (2001) Practical management of iron overload. Br J Haematol 115:239-252
-
(2001)
Br. J. Haematol.
, vol.115
, pp. 239-252
-
-
Porter, J.B.1
-
7
-
-
0031001278
-
Iron-chelation therapy and the treatment of thalassemia
-
Olivieri NF, Brittenham GM (1997) Iron-chelation therapy and the treatment of thalassemia. Blood 89:739-761
-
(1997)
Blood
, vol.89
, pp. 739-761
-
-
Olivieri, N.F.1
Brittenham, G.M.2
-
8
-
-
0006820390
-
An alternative method of subcutaneous deferoxamine administration
-
[abstract]
-
Borgna-Pignatti C, Cohen A (1995) An alternative method of subcutaneous deferoxamine administration Blood 86(Suppl):483 [abstract].
-
(1995)
Blood
, vol.86
, Issue.SUPPL.
, pp. 483
-
-
Borgna-Pignatti, C.1
Cohen, A.2
-
9
-
-
0031765258
-
Subcutaneous bolus injection of deferoxamine in adult patients affected by oncohematological diseases and iron overload
-
Borgna-Pignatti C, Franchini M, Gandini G, Vassanelli A, de Gironcoli M, Aprili G (1998) Subcutaneous bolus injection of deferoxamine in adult patients affected by oncohematological diseases and iron overload. Haematologica 83:788-790
-
(1998)
Haematologica
, vol.83
, pp. 788-790
-
-
Borgna-Pignatti, C.1
Franchini, M.2
Gandini, G.3
Vassanelli, A.4
de Gironcoli, M.5
Aprili, G.6
-
10
-
-
0030961057
-
An alternative to continuous subcutaneous infusion of desferrioxamine in thalassemic patients
-
Di Gregorio F, Romeo MA, Pizzarelli G, Aiello G, Russo G (1997) An alternative to continuous subcutaneous infusion of desferrioxamine in thalassemic patients. Br J Haematol 98:601-602
-
(1997)
Br. J. Haematol.
, vol.98
, pp. 601-602
-
-
Di Gregorio, F.1
Romeo, M.A.2
Pizzarelli, G.3
Aiello, G.4
Russo, G.5
-
11
-
-
20444459918
-
Recent advances in hereditary hemochromatosis
-
Franchini M, Veneri D (2005) Recent advances in hereditary hemochromatosis. Ann Hematol 84:347-352
-
(2005)
Ann. Hematol.
, vol.84
, pp. 347-352
-
-
Franchini, M.1
Veneri, D.2
-
12
-
-
0006844974
-
Relative efficacy of subcutaneous infusion and bolus injections of deferoxamine in the removal of non-transferrin-bound iron (NTBI)
-
[abstract]
-
Porter JB, Srichairatanakool S, Nathan DG, Schinkel H, Gee B, Olivieri NF (1998) Relative efficacy of subcutaneous infusion and bolus injections of deferoxamine in the removal of non-transferrin-bound iron (NTBI) Blood 92(Suppl):668 [abstract].
-
(1998)
Blood
, vol.92
, Issue.SUPPL.
, pp. 668
-
-
Porter, J.B.1
Srichairatanakool, S.2
Nathan, D.G.3
Schinkel, H.4
Gee, B.5
Olivieri, N.F.6
-
13
-
-
0034192162
-
Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload
-
Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, Aprili G (2000) Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood 95:2776-2779
-
(2000)
Blood
, vol.95
, pp. 2776-2779
-
-
Franchini, M.1
Gandini, G.2
de Gironcoli, M.3
Vassanelli, A.4
Borgna-Pignatti, C.5
Aprili, G.6
-
14
-
-
0942276827
-
Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload: An update
-
Franchini M, Gandini G, Veneri D, Aprili G (2004) Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload: An update. Blood 103:747-748
-
(2004)
Blood
, vol.103
, pp. 747-748
-
-
Franchini, M.1
Gandini, G.2
Veneri, D.3
Aprili, G.4
-
16
-
-
0037631496
-
Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity
-
Chaston TB, Richardson DR (2003) Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity. Am J Hematol 73:200-210
-
(2003)
Am. J. Hematol.
, vol.73
, pp. 200-210
-
-
Chaston, T.B.1
Richardson, D.R.2
-
17
-
-
0037630378
-
Role of deferiprone in chelation therapy for transfusional iron overload
-
Hoffbrand AV, Cohen A, Hershko C (2003) Role of deferiprone in chelation therapy for transfusional iron overload. Blood 102:17-24
-
(2003)
Blood
, vol.102
, pp. 17-24
-
-
Hoffbrand, A.V.1
Cohen, A.2
Hershko, C.3
-
19
-
-
0028962119
-
Pharmacokinetics of the oral chelator deferiprone (L1) in patients with iron overload
-
Al-Refaie FN, Shephard LN, Nortey P, Wonke B, Hoffbrand AV (1995) Pharmacokinetics of the oral chelator deferiprone (L1) in patients with iron overload. Br J Haematol 89:403-408
-
(1995)
Br. J. Haematol.
, vol.89
, pp. 403-408
-
-
Al-Refaie, F.N.1
Shephard, L.N.2
Nortey, P.3
Wonke, B.4
Hoffbrand, A.V.5
-
20
-
-
0029097965
-
Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassaemic and sickle red blood cells both in vitro and in vivo
-
Shalev O, Repka T, Goldfarb A, Grinberg L, Abrahamov A, Olivieri NF, Rachmilewitz EA, Hebbel RP (1995) Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassaemic and sickle red blood cells both in vitro and in vivo. Blood 86:2008-2013
-
(1995)
Blood
, vol.86
, pp. 2008-2013
-
-
Shalev, O.1
Repka, T.2
Goldfarb, A.3
Grinberg, L.4
Abrahamov, A.5
Olivieri, N.F.6
Rachmilewitz, E.A.7
Hebbel, R.P.8
-
21
-
-
0038486942
-
Clinical trial of deferiprone iron chelation therapy in β-thalassaemia/haemoglobin E patients in Thailand
-
Pootrakul P, Sirankapracha P, Sankote J, Kachintorn U, Maungsub W, Sriphen K, Thakernpol K, Atisuk K, Fucharoen S, Chantraluksri U, Shalev O, Hoffbrand AV (2003) Clinical trial of deferiprone iron chelation therapy in β-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 122:305-310
-
(2003)
Br. J. Haematol.
, vol.122
, pp. 305-310
-
-
Pootrakul, P.1
Sirankapracha, P.2
Sankote, J.3
Kachintorn, U.4
Maungsub, W.5
Sriphen, K.6
Thakernpol, K.7
Atisuk, K.8
Fucharoen, S.9
Chantraluksri, U.10
Shalev, O.11
Hoffbrand, A.V.12
-
22
-
-
0025130087
-
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). 2. Clinical observations
-
Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ (1990) Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). 2. Clinical observations. Br J Haematol 76:301-304
-
(1990)
Br. J. Haematol.
, vol.76
, pp. 301-304
-
-
Bartlett, A.N.1
Hoffbrand, A.V.2
Kontoghiorghes, G.J.3
-
23
-
-
0025605569
-
L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassemia major
-
Töndury P, Kontoghiorghes GJ, Ridolfi-Lüthy A, Hirt A, Hoffbrand AV, Lottenbach AM, Sonderegger T, Wagner HP (1990) L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassemia major. Br J Haematol 76:550-553
-
(1990)
Br. J. Haematol.
, vol.76
, pp. 550-553
-
-
Töndury, P.1
Kontoghiorghes, G.J.2
Ridolfi-Lüthy, A.3
Hirt, A.4
Hoffbrand, A.V.5
Lottenbach, A.M.6
Sonderegger, T.7
Wagner, H.P.8
-
24
-
-
0026668939
-
Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassemia: Indian trial
-
Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, Puniyani RR, Chhablani AT (1992) Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassemia: Indian trial. Br J Haematol 82:460-466
-
(1992)
Br. J. Haematol.
, vol.82
, pp. 460-466
-
-
Agarwal, M.B.1
Gupte, S.S.2
Viswanathan, C.3
Vasandani, D.4
Ramanathan, J.5
Desai, N.6
Puniyani, R.R.7
Chhablani, A.T.8
-
25
-
-
0029079707
-
Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators
-
Al-Refaie FN, Hershko C, Hoffbrand AV (1995) Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators. Br J Haematol 91:224-229
-
(1995)
Br. J. Haematol.
, vol.91
, pp. 224-229
-
-
Al-Refaie, F.N.1
Hershko, C.2
Hoffbrand, A.V.3
-
26
-
-
0028898064
-
Iron-chelation therapy with oral deferiprone in patients with thalassemia major
-
Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G (1995) Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 332:918-922
-
(1995)
N. Engl. J. Med.
, vol.332
, pp. 918-922
-
-
Olivieri, N.F.1
Brittenham, G.M.2
Matsui, D.3
Berkovitch, M.4
Blendis, L.M.5
Cameron, R.G.6
McClelland, R.A.7
Liu, P.P.8
Templeton, D.M.9
Koren, G.10
-
27
-
-
0029825581
-
Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): A Dutch multicenter trial
-
Kersten MJ, Lange R, Smeets MEP, Vreugdenhil G, Roozendaal KJ, Lameijer W, Goudsmit R (1996) Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): A Dutch multicenter trial. Ann Haematol 73:47-252
-
(1996)
Ann. Haematol.
, vol.73
, pp. 47-252
-
-
Kersten, M.J.1
Lange, R.2
Smeets, M.E.P.3
Vreugdenhil, G.4
Roozendaal, K.J.5
Lameijer, W.6
Goudsmit, R.7
-
28
-
-
0031985039
-
Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients
-
Hoffbrand AV, Al-Refaie F, Davis B (1998) Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 91:295-300
-
(1998)
Blood
, vol.91
, pp. 295-300
-
-
Hoffbrand, A.V.1
Al-Refaie, F.2
Davis, B.3
-
29
-
-
0031873538
-
Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia
-
Mazza P, Amurri B, Lazzari G, Masi C, Palazzo G, Spartera MA, Giua R, Sebastio AM, Suma V, De Marco S, Semeraro F, Moscogiuri R (1998) Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia. Haematologica 83:496-501
-
(1998)
Haematologica
, vol.83
, pp. 496-501
-
-
Mazza, P.1
Amurri, B.2
Lazzari, G.3
Masi, C.4
Palazzo, G.5
Spartera, M.A.6
Giua, R.7
Sebastio, A.M.8
Suma, V.9
De Marco, S.10
Semeraro, F.11
Moscogiuri, R.12
-
30
-
-
0032514558
-
Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
-
Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA (1998) Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 339:417-423
-
(1998)
N. Engl. J. Med.
, vol.339
, pp. 417-423
-
-
Olivieri, N.F.1
Brittenham, G.M.2
McLaren, C.E.3
Templeton, D.M.4
Cameron, R.G.5
McClelland, R.A.6
Burt, A.D.7
Fleming, K.A.8
-
31
-
-
0034044427
-
Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1)
-
Rombos Y, Tzanetea R, Konstantopoulos K, Simitzis S, Zervas C, Kyriaki P, Kavouklis M, Aessopos A, Sakellaropoulos N, Karagiorga M, Kalotychou V, Loukopoulos D (2000) Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica 85:115-117
-
(2000)
Haematologica
, vol.85
, pp. 115-117
-
-
Rombos, Y.1
Tzanetea, R.2
Konstantopoulos, K.3
Simitzis, S.4
Zervas, C.5
Kyriaki, P.6
Kavouklis, M.7
Aessopos, A.8
Sakellaropoulos, N.9
Karagiorga, M.10
Kalotychou, V.11
Loukopoulos, D.12
-
32
-
-
0034517557
-
Factors influencing effectiveness of deferiprone in a thalassemia major clinical setting
-
Del Vecchio GC, Crollo E, Schettini F, Schettini F, Fischer R, De Mattia D (2000) Factors influencing effectiveness of deferiprone in a thalassemia major clinical setting. Acta Haematol 104:99-102
-
(2000)
Acta Haematol.
, vol.104
, pp. 99-102
-
-
Del Vecchio, G.C.1
Crollo, E.2
Schettini, F.3
Schettini, F.4
Fischer, R.5
De Mattia, D.6
-
33
-
-
0034883496
-
Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients
-
Taher A, Sheik-Taha M, Koussa S, Inati A, Neeman R, Mourad F (2001) Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur J Haematol 67:30-34
-
(2001)
Eur. J. Haematol.
, vol.67
, pp. 30-34
-
-
Taher, A.1
Sheik-Taha, M.2
Koussa, S.3
Inati, A.4
Neeman, R.5
Mourad, F.6
-
34
-
-
18444390877
-
Deferiprone versus deferoxamine in patients with thalassemia major: A randomized clinical trial
-
Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, Di Gregorio F, Garozzo G, Malizia R, Magnano C, Mangiagli A, Quarta G, Rizzo M, D'Ascola DG, Rizzo A, Midiri M (2002) Deferiprone versus deferoxamine in patients with thalassemia major: A randomized clinical trial. Blood Cells Mol Dis 28:196-208
-
(2002)
Blood Cells Mol. Dis.
, vol.28
, pp. 196-208
-
-
Maggio, A.1
D'Amico, G.2
Morabito, A.3
Capra, M.4
Ciaccio, C.5
Cianciulli, P.6
Di Gregorio, F.7
Garozzo, G.8
Malizia, R.9
Magnano, C.10
Mangiagli, A.11
Quarta, G.12
Rizzo, M.13
D'Ascola, D.G.14
Rizzo, A.15
Midiri, M.16
-
35
-
-
0036068230
-
The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients
-
Ceci A, Baiardi P, Felisi M (2002) The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 118:330-336
-
(2002)
Br. J. Haematol.
, vol.118
, pp. 330-336
-
-
Ceci, A.1
Baiardi, P.2
Felisi, M.3
-
36
-
-
0042943205
-
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone
-
Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F (2003) Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 102:1583-1587
-
(2003)
Blood
, vol.102
, pp. 1583-1587
-
-
Cohen, A.R.1
Galanello, R.2
Piga, A.3
De Sanctis, V.4
Tricta, F.5
-
37
-
-
14044266868
-
Safety of oral iron chelator deferiprone in young thalassaemics
-
Naithani R, Chandra J, Sharma S (2005) Safety of oral iron chelator deferiprone in young thalassaemics. Eur J Haematol 74:217-220
-
(2005)
Eur. J. Haematol.
, vol.74
, pp. 217-220
-
-
Naithani, R.1
Chandra, J.2
Sharma, S.3
-
39
-
-
4544237005
-
Iron-chelation therapy: An update
-
Franchini M, Veneri D (2004) Iron-chelation therapy: An update. Hematol J 5:287-292
-
(2004)
Hematol. J.
, vol.5
, pp. 287-292
-
-
Franchini, M.1
Veneri, D.2
-
40
-
-
0037930751
-
Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: Application of SQUID biomagnetic liver susceptometry
-
Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A (2003) Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 121:938-948
-
(2003)
Br. J. Haematol.
, vol.121
, pp. 938-948
-
-
Fischer, R.1
Longo, F.2
Nielsen, P.3
Engelhardt, R.4
Hider, R.C.5
Piga, A.6
-
41
-
-
0037125595
-
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia
-
Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennel DJ (2002) Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 360:516-520
-
(2002)
Lancet
, vol.360
, pp. 516-520
-
-
Anderson, L.J.1
Wonke, B.2
Prescott, E.3
Holden, S.4
Walker, J.M.5
Pennel, D.J.6
-
42
-
-
0038187626
-
Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: A retrospective analysis
-
Piga A, Gaglioti C, Fogliacco E, Tricta F (2003) Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: A retrospective analysis. Haematologica 88:489-496
-
(2003)
Haematologica
, vol.88
, pp. 489-496
-
-
Piga, A.1
Gaglioti, C.2
Fogliacco, E.3
Tricta, F.4
-
43
-
-
2942616383
-
Purging iron from the heart
-
Hershko C, Cappellini MD, Galanello R, Piga A, Tognoni G, Masera G (2004) Purging iron from the heart. Br J Haematol 125:545-551
-
(2004)
Br. J. Haematol.
, vol.125
, pp. 545-551
-
-
Hershko, C.1
Cappellini, M.D.2
Galanello, R.3
Piga, A.4
Tognoni, G.5
Masera, G.6
-
44
-
-
0034094839
-
Safety profile of the oral iron chelator deferiprone: A multicenter study
-
Cohen AR, Galanello R, Piga A, DiPalma A, Vullo C, Tricta F (2000) Safety profile of the oral iron chelator deferiprone: A multicenter study. Br J Haematol 108:305-312
-
(2000)
Br. J. Haematol.
, vol.108
, pp. 305-312
-
-
Cohen, A.R.1
Galanello, R.2
Piga, A.3
DiPalma, A.4
Vullo, C.5
Tricta, F.6
-
45
-
-
0032481133
-
Iron chelation with oral deferiprone in patients with thalassemia
-
[letter]
-
Grady RW, Giardina PJ (1998) Iron chelation with oral deferiprone in patients with thalassemia N Engl J Med 339:1712-1713 [letter].
-
(1998)
N. Engl. J. Med.
, vol.339
, pp. 1712-1713
-
-
Grady, R.W.1
Giardina, P.J.2
-
46
-
-
0036721452
-
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia
-
Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, Gamberini MR, Schwartz E, Cohen AR (2002) Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 100:1566-1569
-
(2002)
Blood
, vol.100
, pp. 1566-1569
-
-
Wanless, I.R.1
Sweeney, G.2
Dhillon, A.P.3
Guido, M.4
Piga, A.5
Galanello, R.6
Gamberini, M.R.7
Schwartz, E.8
Cohen, A.R.9
-
47
-
-
0031859182
-
Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients
-
Tondury P, Zimmermann A, Nielsen P, Hirt A (1998) Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol 101:413-415
-
(1998)
Br. J. Haematol.
, vol.101
, pp. 413-415
-
-
Tondury, P.1
Zimmermann, A.2
Nielsen, P.3
Hirt, A.4
-
48
-
-
7044227861
-
Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias
-
Kwiatkowski JL, Cohen AR (2004) Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias. Hematol Oncol Clin N Am 18:1355-1377
-
(2004)
Hematol. Oncol. Clin. N. Am.
, vol.18
, pp. 1355-1377
-
-
Kwiatkowski, J.L.1
Cohen, A.R.2
-
49
-
-
0035865702
-
ICL670A: A new synthetic oral chelator: Evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture
-
Hershko C, Konijn AM, Nick HP, Breuer V, Cabantchik ZI, Link G (2001) ICL670A: A new synthetic Eral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 97:1115-1122
-
(2001)
Blood
, vol.97
, pp. 1115-1122
-
-
Hershko, C.1
Konijn, A.M.2
Nick, H.P.3
Breuer, V.4
Cabantchik, Z.I.5
Link, G.6
-
50
-
-
0037906104
-
Safety, tolerability and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia
-
Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Séchaud R (2003) Safety, tolerability and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J Clin Pharmacol 43:565-572
-
(2003)
J. Clin. Pharmacol
, vol.43
, pp. 565-572
-
-
Galanello, R.1
Piga, A.2
Alberti, D.3
Rouan, M.C.4
Bigler, H.5
Séchaud, R.6
-
51
-
-
10744230223
-
Effectiveness and safety of ICL670 in iron-loaded patients with thalassemia: A randomised, double-blind, placebo-controlled, dose-escalation trial
-
Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC, Nathan DG (2003) Effectiveness and safety of ICL670 in iron-loaded patients with thalassemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 361:1597-1602
-
(2003)
Lancet
, vol.361
, pp. 1597-1602
-
-
Nisbet-Brown, E.1
Olivieri, N.F.2
Giardina, P.J.3
Grady, R.W.4
Neufeld, E.J.5
Sechaud, R.6
Krebs-Brown, A.J.7
Anderson, J.R.8
Alberti, D.9
Sizer, K.C.10
Nathan, D.G.11
-
52
-
-
1542352269
-
Phase II study of ICL670, an oral chelator, in adult thalassemia patients with transfusional iron overload: Efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy
-
Piga A, Galanello R, Cappellini MD, Forni G-L, Lupo G, Ford JM (2003) Phase II study of ICL670, an oral chelator, in adult thalassemia patients with transfusional iron overload: Efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood 102:121a
-
(2003)
Blood
, vol.102
-
-
Piga, A.1
Galanello, R.2
Cappellini, M.D.3
Forni, G.-L.4
Lupo, G.5
Ford, J.M.6
-
53
-
-
14644392013
-
Thalassemia
-
(Am Soc Hematol Educ Program):
-
Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E (2004) Thalassemia. Hematology 14-34 (Am Soc Hematol Educ Program):
-
(2004)
Hematology
, pp. 14-34
-
-
Cohen, A.R.1
Galanello, R.2
Pennell, D.J.3
Cunningham, M.J.4
Vichinsky, E.5
-
55
-
-
0031784438
-
Combined therapy with deferiprone and desferrioxamine
-
Wonke B, Wright C, Hoffbrand AV (1998) Combined therapy with deferiprone and desferrioxamine. Br J Haematol 103:361-364
-
(1998)
Br. J. Haematol.
, vol.103
, pp. 361-364
-
-
Wonke, B.1
Wright, C.2
Hoffbrand, A.V.3
-
56
-
-
0034491797
-
Combined oral and parenteral iron chelation in beta thalassaemia major
-
Balveer K, Pyar K, Wonke B (2000) Combined oral and parenteral iron chelation in beta thalassaemia major. Med J Malays 55:493-497
-
(2000)
Med. J. Malays
, vol.55
, pp. 493-497
-
-
Balveer, K.1
Pyar, K.2
Wonke, B.3
-
57
-
-
0032820582
-
Sequential use of deferiprone and desferrioxamine in primary school children with thalassemia major in Turkey
-
Aydinok Y, Nisli G, Kavakli K (1999) Sequential use of deferiprone and desferrioxamine in primary school children with thalassemia major in Turkey. Acta Haematol 102:17-21
-
(1999)
Acta Haematol.
, vol.102
, pp. 17-21
-
-
Aydinok, Y.1
Nisli, G.2
Kavakli, K.3
-
58
-
-
0037761473
-
Combined iron chelation therapy with desferrioxamine and deferiprone in β-thalassemic patients
-
Alymara V, Bourantas DK, Chaidos A (2002) Combined iron chelation therapy with desferrioxamine and deferiprone in β-thalassemic patients. Hematol J 3(Suppl 1):81
-
(2002)
Hematol J.
, vol.3
, Issue.SUPPL. 1
, pp. 81
-
-
Alymara, V.1
Bourantas, D.K.2
Chaidos, A.3
-
59
-
-
0037761474
-
Safety and efficacy of combining deferiprone and deferoxamine in iron chelation therapy in patients with thalassemia
-
Kattamis A, Kassou C, Ladis V (2002) Safety and efficacy of combining deferiprone and deferoxamine in iron chelation therapy in patients with thalassemia. Blood 100:11
-
(2002)
Blood
, vol.100
, pp. 11
-
-
Kattamis, A.1
Kassou, C.2
Ladis, V.3
-
60
-
-
0242584372
-
Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassemia patients
-
Mourad FH, Hoffbrand AV, Sheik-Taha M, Koussa S (2003) Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassemia patients. Br J Haematol 121:187-189
-
(2003)
Br. J. Haematol.
, vol.121
, pp. 187-189
-
-
Mourad, F.H.1
Hoffbrand, A.V.2
Sheik-Taha, M.3
Koussa, S.4
-
61
-
-
0038438059
-
Combination of desferrioxamine and deferiprone markedly enhance iron excretion
-
Grady RW, Berdoukas V, Rachmilewitz EA (2002) Combination of desferrioxamine and deferiprone markedly enhance iron excretion. Blood 100:241a
-
(2002)
Blood
, vol.100
-
-
Grady, R.W.1
Berdoukas, V.2
Rachmilewitz, E.A.3
-
62
-
-
0035254193
-
Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy
-
Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI (2001) Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood 97:792-798
-
(2001)
Blood
, vol.97
, pp. 792-798
-
-
Breuer, W.1
Ermers, M.J.2
Pootrakul, P.3
Abramov, A.4
Hershko, C.5
Cabantchik, Z.I.6
-
63
-
-
0018798539
-
A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents
-
Ponka P, Borova J, Neuwirt J, Fuchs O, Necas E (1979) A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta 586:278-297
-
(1979)
Biochim. Biophys. Acta
, vol.586
, pp. 278-297
-
-
Ponka, P.1
Borova, J.2
Neuwirt, J.3
Fuchs, O.4
Necas, E.5
-
64
-
-
0032055861
-
Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease
-
Richardson DR, Ponka P (1998) Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med 131:306-315
-
(1998)
J. Lab. Clin. Med.
, vol.131
, pp. 306-315
-
-
Richardson, D.R.1
Ponka, P.2
-
65
-
-
0025194404
-
Pyridoxal isonicotinoyl hydrazone: An effective iron-chelator after oral administration
-
Brittenham GM (1990) Pyridoxal isonicotinoyl hydrazone: An effective iron-chelator after oral administration. Semin Hematol 27:112-116
-
(1990)
Semin. Hematol.
, vol.27
, pp. 112-116
-
-
Brittenham, G.M.1
-
66
-
-
0038603210
-
Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells
-
Link G, Ponka P, Konijn AM, Breuer W, Cabantchik ZI, Hershko C (2003) Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. Blood 101:4172-4179
-
(2003)
Blood
, vol.101
, pp. 4172-4179
-
-
Link, G.1
Ponka, P.2
Konijn, A.M.3
Breuer, W.4
Cabantchik, Z.I.5
Hershko, C.6
-
68
-
-
0037089226
-
HBED ligand: Preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning
-
Bergeron RJ Wiegand J, Brittenham GM (2002) HBED ligand: Preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Blood 99:3019-3026
-
(2002)
Blood
, vol.99
, pp. 3019-3026
-
-
Bergeron, R.J.1
Wiegand, J.2
Brittenham, G.M.3
|